Landscapes / Companies
Gedeon Richter Plc. not checked
FollowEvery new trial, moved date and filing, and a Monday email
Drugs
3
in active trials · 5 in all
Trials
3 active
8 since 2021
Drugs3
| Drug | How it works | Partner | Stage
Sources: FDA: the drug development process, ClinicalTrials.gov glossary | Next date
| Details |
|---|---|---|---|---|---|
Atypical antipsychotic |
AbbVie |
Approved | 15 Dec 2026soonPhase 3 trial completes | ||
| Next date | 15 Dec 2026 · Phase 3 trial completes | ||||
| Also tested for | Schizophrenia | ||||
| Open drug page | |||||
RGH-202not checked |
— |
Phase 2 | 13 Feb 2028Phase 2 trial completes | ||
| Next date | 13 Feb 2028 · Phase 2 trial completes | ||||
| Also tested for | Social Anxiety Disorder | ||||
| Open drug page | |||||
Angiotensin II receptor antagonist |
Phase 1 | — | |||
| How it works | Blocks the effect of angiotensin II | ||||
| Also tested for | Hypertension | ||||
| Open drug page | |||||
About
- SEC filings
- None: it does not file with the US SEC
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 Industry-sponsored drug trials since 2021